0000000000240341

AUTHOR

Guillaume Cayla

showing 6 related works from this author

Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile

2020

Aim: to evaluate the impact of a nationwide lockdown in France on acute myocardial infarction (AMI) admissions, by patient characteristics and regional prevalence of the pandemic. Methods and Results: We collected data from 21 centres participating in the on-going FRENCHIE registry (NCT04050956), which collects data from all patients admitted for STEMI or NSTEMI within 48 hours of symptom onset. We compared weekly admissions in the 4 weeks preceding and the 4 weeks following institution of the lockdown. We observed a brutal 30% decrease in AMI admissions (24% for STEMI and 36% for NSTEMI, P=0.14) following institution of the lockdown, with similar trends according to gender (30% decrease in…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryFamily medicineHospital admissionmedicinePatient profilePatient characteristicsIn patientSymptom onsetbusinessRegulatory authoritySSRN Electronic Journal
researchProduct

Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and no…

2020

Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age.The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients.The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years.Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, tha…

Malemedicine.medical_specialty[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismFamilial hypercholesterolemia030204 cardiovascular system & hematologyCohort StudiesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineSurveys and QuestionnairesInternal MedicinemedicineHumansIn patient030212 general & internal medicineMyocardial infarctionRegistriesNon-ST Elevated Myocardial InfarctionStrokeComputingMilieux_MISCELLANEOUSAgedNutrition and Dieteticsbusiness.industryST elevationHazard ratioMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthCohortST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFemaleFranceHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessJournal of clinical lipidology
researchProduct

Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in Fra…

2020

Background The COVID-19 pandemic has had a profound effect on general health care. We aimed to evaluate the effect of a nationwide lockdown in France on admissions to hospital for acute myocardial infarction, by patient characteristics and regional prevalence of the pandemic. Methods In this registry study, we collected data from 21 centres participating in the ongoing French Cohort of Myocardial Infarction Evaluation (FRENCHIE) registry, which collects data from all patients admitted for ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI) within 48 h of symptom onset. We analysed weekly hospital admissions over 8 weeks: the 4 weeks …

Malemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralMyocardial InfarctionRate ratio01 natural sciencesCohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicinePatient Admission[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsPrevalenceMedicineST segmentHumans030212 general & internal medicinePoisson regressionMyocardial infarctionRegistries0101 mathematicsPandemicsAgedAged 80 and overbusiness.industry010102 general mathematicsPublic Health Environmental and Occupational HealthCOVID-19ArticlesMiddle Agedmedicine.disease3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieEmergency medicineCohortsymbolsObservational studyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusinessCoronavirus InfectionsCohort study
researchProduct

ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.

2021

Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown.Aim: To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019.Methods: In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or no…

MaleMESH: Hyperlipidemiasmedicine.medical_treatmentMESH: ComorbidityComorbidity030204 cardiovascular system & hematologyMESH: Health Care SurveysMESH: HypertensionMESH: Procedures and Techniques Utilization0302 clinical medicinePatient AdmissionInterquartile rangeMESH: Risk FactorsRisk FactorsST segmentMESH: COVID-19030212 general & internal medicineMyocardial infarctionHospital MortalityMESH: Treatment Outcomeeducation.field_of_studyMESH: Middle AgedCardiogenic shockSmokingMESH: Patient Acceptance of Health CareGeneral MedicineMESH: Heart Rupture Post-InfarctionMiddle AgedPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTreatment OutcomeHypertensionCardiologyFemaleStentsFranceCardiology and Cardiovascular MedicineSCA ST+MESH: Percutaneous Coronary Interventionmedicine.medical_specialtyMESH: PandemicsMESH: SmokingMESH: Diabetes MellitusPopulationComplications mécaniquesHyperlipidemiasRevascularizationMESH: PrognosisTime-to-TreatmentSTEMI03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineLockdownmedicineDiabetes MellitusHumansMESH: SARS-CoV-2MESH: Time-to-TreatmentMESH: Hospital MortalityMESH: ST Elevation Myocardial InfarctioneducationPandemicsHeart Rupture Post-InfarctionMESH: Humansbusiness.industryMESH: Patient AdmissionSARS-CoV-2Percutaneous coronary interventionCOVID-19Patient Acceptance of Health Caremedicine.diseaseComorbidityMESH: MaleMESH: FranceMESH: Stents[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care SurveysST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMechanical complicationsbusinessMESH: FemaleProcedures and Techniques UtilizationConfinementArchives of cardiovascular diseases
researchProduct

Temporal Trends in Transcatheter Aortic Valve Replacement in France

2017

Background - Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. Objectives - The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. Methods - TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwa…

Aortic valvemedicine.medical_specialtymedicine.medical_treatmentnational registry030204 cardiovascular system & hematologyoutcomes03 medical and health sciences0302 clinical medicineValve replacementCardiac tamponadeMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSAortic dissectionbusiness.industryMortality ratetransfemoralEuroSCORE[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasepacemaker3. Good healthSurgeryStenosisCathetermedicine.anatomical_structureCardiology and Cardiovascular Medicinebusiness
researchProduct

Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-…

2019

Abstract Aims ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). Methods and results The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme c…

medicine.medical_specialtyPercutaneousmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionAcute myocardial infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic Agents[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFibrinolysismedicineHumansST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesTimingPrimary PCIbusiness.industryFibrinolysisHazard ratioPercutaneous coronary interventionmedicine.diseaseLong-term outcome3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV] Life Sciences [q-bio]Treatment OutcomeEmergency medicineConventional PCIST Elevation Myocardial InfarctionCardiology and Cardiovascular Medicinebusiness
researchProduct